Clinical application of botulinum toxin A in adult tic disorders
10.3760/cma.j.cn113694-20250510-00272
- VernacularTitle:A型肉毒毒素治疗在成人抽动障碍中的临床应用
- Author:
Dandan XIE
1
;
Yang LI
1
;
Xinhua WAN
1
Author Information
1. 中国医学科学院北京协和医学院 北京协和医院神经科，北京100730
- Publication Type:Journal Article
- Keywords:
Tic movement disorder;
Botulinum toxins, type A;
Chronic motor or vocal tic disorder;
Treatment outcome
- From:
Chinese Journal of Neurology
2025;58(9):930-937
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of botulinum toxin type A (BTX-A) injections in treating motor tics in adult patients with tic disorders.Methods:A retrospective analysis was conducted on the baseline and clinical data of 25 adult tic disorder patients who received BTX-A treatment at the Movement Disorders Clinic of the Department of Neurology, Peking Union Medical College Hospital, from January 2019 to July 2023. Before the treatment, the Yale Global Tic Severity Scale (YGTSS) was used to assess the severity of motor and vocal tics. The injection sites and dosage of BTX-A were determined based on the distribution and severity of tic symptoms. Post-treatment improvement was evaluated via telephone follow-up.Results:Among the 25 patients, 18 were male and 7 were female, with an age of 27.0 (23.5, 31.0) years and a disease duration of 10.0 (5.5, 18.5) years. The pre-treatment YGTSS score was 41.3±12.3. After treatment, the time to onset of effect was 2.0 (1.0, 5.0) days, the peak efficacy was achieved at (15.5±9.4) days, and the duration of efficacy was 4.0 (2.5, 6.0) months. Post-treatment YGTSS score decreased to 14.7±11.3, with an improvement rate of 63.7%±24.9%. Significant efficacy was observed in 68.0% (17/25) of patients, 28% (7/25) showed moderate improvement, and 4% (1/25) had no response. Anxiety symptoms were alleviated in 91% (21/24) of patients, and premonitory urges were reduced in 90% (18/20) of patients. Retreatment in 13 patients with symptom recurrence remained effective. Adverse effects included facial stiffness in 4 patients, scalp tightness in 1, and mild neck muscle weakness in 5, all of which resolved spontaneously within 3-14 days; 16 patients reported no adverse effects.Conclusion:BTX-A is safe and effective in controlling motor tics in adult patients with tic disorders.
